Mangoceuticals (NASDAQ:MGRX) Shares Surge Almost Threefold Following Nuclea Agreement; Existing Shareholders Retain 4%

Mangoceuticals shares surged almost threefold on Friday morning following the announcement of a nuclear reverse merger. The stock traded at $0.8029, marking a 173.5% increase from the previous day's close, after touching a high of $1.23 earlier. Trading volume surpassed 350.5 million shares.

NASDAQ:MGRX · Pharmaceuticals · Stock Market
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc., the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy.GlobeNewswire+1
13 November 2025
····
Follow on Google News
Add as preferred source Open in Google News